Drug-resistant epilepsy
Conditions
Interventions
Case Group (Drug-Resistant Epilepsy):None
Control Group (Non-Epilepsy):None
Sponsors
The second affiliated hospital of Army medical university
Eligibility
Sex/Gender
All
Age
No minimum to 90 Years
Inclusion criteria
Inclusion criteria: 1. Case Group (Drug-Resistant Epilepsy): Patients diagnosed with drug-resistant epilepsy and scheduled for epileptogenic focus resection. Inclusion criteria for the case group: (1) Age >=1 month and =18 years). 2. Control Group (Non-Epilepsy): Patients undergoing surgery for other neurosurgical conditions (e.g., acute intracranial hemorrhage within 24 hours, craniotomy with aneurysm clipping for non-epilepsy reasons) and without systemic immune system diseases, matched for age and gender with the case group. Inclusion criteria for the control group: (1) Age >=1 month and <=90 years. (2) Undergoing craniotomy for non-epilepsy-related reasons (e.g., acute intracranial hemorrhage within 24 hours, craniotomy with aneurysm clipping for non-epilepsy reasons). (3) No history of epilepsy, no other neurological disease diagnosis, and no diseases affecting immune function. (4) The patient or family member is able to understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for the case group (drug-resistant epilepsy group): (1) Coexisting other severe neurological diseases (such as brain tumor, stroke, multiple sclerosis, etc.). (2) Coexisting severe immune system diseases or autoimmune disorders. (3) Suffering from severe systemic infection or inflammatory disease. (4) Receiving treatments that may affect immune response (such as chemotherapy, radiotherapy, immunosuppressive therapy, etc.). (5) Pregnant or lactating women. (6) History of psychiatric illness, unable to cooperate with the study. 2. Exclusion criteria for the control group (non-epilepsy): (1) Coexisting severe immune system diseases or autoimmune disorders. (2) Suffering from severe systemic infection or inflammatory disease. (3) Receiving treatments that may affect immune response. (4) Pregnant or lactating women. (5) History of psychiatric illness, unable to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composition of immune cell subsets and enriched molecular signaling pathways in skull bone marrow; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composition, quantity, and activation status of B cells, T cells, and myeloid cells in meninges;Immune cell infiltration and functional status in choroid plexus;Expression levels of inflammatory cytokines and chemokines, and activation status of microglia and astrocytes in epileptogenic focus;Differentially expressed key genes and proteins in skull bone marrow, meninges, choroid plexus, and epileptogenic focus (especially related to cell migration, adhesion, and immune regulation);Statistical correlation between key immune cell subset proportions or core molecular pathway features in skull bone marrow and seizure frequency, seizure severity, and drug-resistant status;Levels of inflammatory cytokines, chemokines, and cell damage markers in peripheral blood; | — |
Countries
China
Contacts
Public ContactZhang Chunqing
The second affiliated hospital of Army medical university
Outcome results
None listed